On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF
Kittipibul V, Mentz R, Clare R, Wojdyla D, Anstrom K, Eisenstein E, Ambrosy A, Goyal P, Skopicki H, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Greene S. On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF. European Journal Of Heart Failure 2024, 26: 1518-1523. PMID: 38745502, PMCID: PMC11269016, DOI: 10.1002/ejhf.3293.Peer-Reviewed Original ResearchOn-treatment analysisFollow-upAll-cause mortalityHeart failureOn-treatmentNo significant differenceNon-adherencePost-hocSignificant differenceTime of hospital dischargePost hoc analysisDiuretic statusPatients on-treatmentTorsemide groupOpen-labelFurosemide groupRandomized patientsTRANSFORM-HFHF hospitalizationRandomized trialsFurosemidePatientsTorsemideHospital outcomesOutcome differencesImpact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF
Martens P, Greene S, Mentz R, Li S, Wojdyla D, Kapelios C, Mullens W, Hall M, Ketema F, Kim D, Eisenstein E, Anstrom K, Fang J, Pitt B, Velazquez E, Tang W. Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF. European Journal Of Heart Failure 2024, 26: 1242-1250. PMID: 38558520, DOI: 10.1002/ejhf.3207.Peer-Reviewed Original ResearchEffect of torsemideBaseline renal functionRenal functionHeart failureKCCQ-CSSRandomized patientsKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreSpectrum of renal functionBaseline kidney dysfunctionCategories of estimated glomerular filtration rateTrial randomized patientsClinical summary scoreAdverse clinical outcomesGlomerular filtration rateAll-cause mortalityTreatment effect modificationModify treatment effectsPost hoc analysisPatient-reported outcomesDiuretic efficacyBaseline eGFRNo significant differenceClinical outcomesKidney dysfunctionFiltration rateTorsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF
Kapelios C, Greene S, Mentz R, Ikeaba U, Wojdyla D, Anstrom K, Eisenstein E, Pitt B, Velazquez E, Fang J, Investigators T. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF. Circulation Heart Failure 2024, 17: e011246. PMID: 38436075, PMCID: PMC10950535, DOI: 10.1161/circheartfailure.123.011246.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionLVEF groupsKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreMildly reduced left ventricular ejection fractionBaseline left ventricular ejection fractionReduced left ventricular ejection fractionClinical summary scoreHeart failureNo significant differenceEjection fractionClinical outcomesLVEF spectrumSignificant differenceLeft ventricular ejection fraction dataEnd pointsSpectrum of ejection fractionEffect of torsemideRisk of clinical outcomesVentricular ejection fractionStudy end pointBaseline patient characteristicsClinical end pointsSummary scoreAll-cause mortalityPrevalence of comorbidities